Akita Satori, Fujibayashi Kosuke, Ueno Ei-Ichi, Wakasa Minoru, Kawai Yasuyuki, Kajinami Kouji
Department of Cardiology, Kanazawa Medical University, Japan.
Intern Med. 2024 Apr 15;63(8):1113-1117. doi: 10.2169/internalmedicine.1846-23. Epub 2023 Sep 1.
A 54-year-old woman with multiple sclerosis treated with interferon-β (IFN-β)-1b for 15 years presented with sustained hypertension (240/124 mmHg) and retinal bleeding. She had proteinuria, anemia, thrombocytopenia, elevated serum creatinine levels, and haptoglobin depletion. Intravenous nicardipine stabilized her blood pressure, but her renal function and platelet count deteriorated. The initial disintegrin-like metalloprotease with thrombospondin type 1 motifs 13 (ADAMTS13) activity was 28% of normal without its inhibitor. The subsequent peripheral appearance of schistocytes suggested thrombotic microangiopathy (TMA). After IFN-β-1b cessation, the platelet count increased, and the blood pressure stabilized. The ADAMTS13 activity normalized, although the creatinine level did not. TMA may develop after the long-term use of IFN-β without adverse events.
一名54岁的女性,患多发性硬化症,使用β-干扰素(IFN-β)-1b治疗15年,出现持续性高血压(240/124 mmHg)和视网膜出血。她有蛋白尿、贫血、血小板减少、血清肌酐水平升高和触珠蛋白消耗。静脉注射尼卡地平使她的血压稳定,但她的肾功能和血小板计数恶化。最初,具有1型血小板反应蛋白基序的去整合素样金属蛋白酶13(ADAMTS13)活性在无抑制剂的情况下为正常水平的28%。随后外周血出现裂红细胞提示血栓性微血管病(TMA)。停用IFN-β-1b后,血小板计数增加,血压稳定。尽管肌酐水平未恢复正常,但ADAMTS13活性恢复正常。长期使用IFN-β后可能会发生TMA且无不良事件。